Summit Therapeutics Share Discussion Threads

[hugus maximus] 24/12/2017 09:00

Flip ... that's an unexpected one and needs some time to research & digest.

[football] 24/12/2017 00:00

SUMMIT OBTAINS INNOVATIVE ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM THROUGH ACQUISITION OF DISCUVA LTD

Positions Summit as a Leader in Research & Development of New Classes of Antibiotics
Enhances Summit's Broader Business in Rare and Infectious Diseases
Supports Mission to Discover and Develop Therapies for Patients in Areas of Substantial Unmet Need
Conference Call to be Held 3 January 2018, 1:00pm GMT / 8:00am EST
Oxford, UK, 23 December 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for rare diseases and infectious diseases, announces it has obtained an innovative research and development platform for the generation of differentiated antibiotic compounds through its acquisition of Discuva Limited ('Discuva'), a privately held UK-based company. The acquisition expands Summit's interests in infectious diseases that are led by its flagship precision C. difficile infection ('CDI') antibiotic candidate ridinilazole. The Company is now better placed to advance additional potential drug treatments for patients with serious bacterial infections where there is substantial unmet need, while in parallel continuing to advance its clinical and research programme in Duchenne muscular dystrophy.

"The global threat from multi-drug resistant bacterial infections continues to rise. There are few new antibiotics in development, with most of those being iterations of known classes of antibiotics, meaning there is an urgent need for the development of novel antibiotics," commented Mr Glyn Edwards, Chief Executive Officer of Summit. "With the acquisition, Summit is positioned as a leader in the research and development of new classes of antibiotics as exemplified by our precision antibiotic candidate ridinilazole for the treatment of C. difficile infection. Using this platform, we aim to generate a pipeline of new mechanism of action antibiotics that address other serious infectious disease threats."

"Our vision is to prioritise the development of novel antibiotics against pathogens where an urgent unmet need exists and we have the ability to show advantages over current treatments," added Dr David Roblin, Chief Operating Officer and President of Research and Development of Summit. "The addition of this platform, coupled with our expertise in the discovery and clinical development of antibiotics, positions us to create new classes of antibiotics that target current and emergent bacterial threats for which there are only inadequate therapies."

The proprietary bacterial genetics-based platform facilitates the discovery and development of novel, differentiated antibiotics. This platform combines transposon technology with bioinformatics to create a powerful tool to identify new antibacterial drug targets, elucidate antibiotic mechanisms of action and optimise against bacterial resistance to generate new antibiotic drug candidates.

The platform is utilising proprietary libraries of multiple pathogens associated with antibiotic resistance. These provide excellent coverage against the ESKAPE pathogens, a leading cause of multi-drug resistance and hospital acquired infections throughout the world, and pathogens listed as urgent or serious threats by the US Centers for Disease Control. With activity demonstrated against a number of these bacterial targets, and a research collaboration between Discuva and Roche, the platform has already shown promise.


read more

[football] 23/12/2017 23:59

is this new on summite website tonight?

Infectious Disease Discovery
The proprietary bacterial genetics-based platform facilitates the discovery and development of novel, differentiated antibiotics. This platform combines transposon technology with bioinformatics to create a powerful tool to identify new antibacterial drug targets, elucidate antibiotic mechanisms of action and optimise against bacterial resistance to generate new antibiotic drug candidates.

The platform is utilising proprietary libraries of multiple pathogens associated with antibiotic resistance. These provide excellent coverage against the ESKAPE pathogens, a leading cause of multi-drug resistance and hospital acquired infections throughout the world, and pathogens listed as urgent or serious threats by the US Centers for Disease Control. With activity demonstrated against a number of these bacterial targets, and a research collaboration between Discuva and Roche, the platform has already shown promise.

[chrisatrdg] 23/12/2017 21:17

This is mind blowing & is a company I know & it is at the cutting edge of Antibiotic Discovery - the share price will rocket next week (Edit: Maybe).

SUMMIT OBTAINS INNOVATIVE ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM THROUGH ACQUISITION OF DISCUVA LTD.

[someuwin] 23/12/2017 21:08

Summit Therapeutics‏ @Summitplc · 5 minutes ago

Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd.: …

[luminoso] 21/12/2017 22:20

Quite a good reaction on the nasdaq, but will it hold ? These are relatively small numbers though and the milestone payments will take some time coming. So plenty of cash needed still for P3 Rid. A deal on European rights seems necessary to nail the funding for P3... and to excite the markets ?

[hugus maximus] 21/12/2017 08:46

Great news ... perhaps investors will see this as a turning point for the share price in the USA? After selling for end of year tax loss purposes, the share price was bound to move up toward Q1 2018 DMD results. SUM impetus to turn things back toward the New Year?!

[abergele] 21/12/2017 08:43

Gla lth's here,and a Merry Xmas to you H.al..
just a small topup as this is great news.

[waterloo01] 21/12/2017 08:11

If they follow the same path as with EZT then we might well get a European rights deal keeping US and rest of the world. The funding will help as they contribute as the phase 3 trials progress. An EU deal might well see the rest of the funding sorted.

[football] 21/12/2017 08:09

Commercialisation - it's been a long time coming but lets hope the wait is over in 2018

[waterloo01] 21/12/2017 07:33

Interesting. Does suggest other deals based on geography might be forthcoming.

[gersemi] 21/12/2017 07:06

Very nice indeed

[freemoney2] 18/12/2017 14:14

stephen2010, interesting write up of oil stocks.... wrong board by accident or trying to peak interests in Summit alternative investments ?

Since you're here though which do you invest in and prefer, UKOG or ALBA ?

Summit will rerate in 2018 I'm sure. Not sure of the timing though, which will happen first, SUMM, UKOG or ALBA.

The similarities between investing in Pharma and Oil/mineral exploration is very interesting from an investor point of view. Binary gambles with huge potential rewards on the table.

Good luck all and happy Christmas whatever you are invested in and how you are playing them. GLA

[waterloo01] 16/12/2017 14:36

Although I've seen the Panmure note, I've not seen it anywhere else, even Research Tree doesn't carry it. Shame as it makes a decent read. Target price of £3.42

[stephen2010] 14/12/2017 22:24

ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following:

MARKET CAP PUZZLE
❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed
companies with much enhanced market capitalisations, such as UKOG.L (£134m) and
JAY.L (£172m). With either shared project interests or adjacent tenements to these
companies, Alba should trade at a much higher valuation than its current token value.
Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG
are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse
Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba
has approximately one third of the value of Horse Hill compared to UKOG but only
about 7% of the market capitalisation. Once the market recognises these disparities,
the room for growth in Alba’s share price is undeniable.

VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note
uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The
Horse Hill licences are valued using independent published technical data from
Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own
assumptions on recovery rates, oil discovery value, resource and development risks
factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived
for Horse Hill.

Given the similar geology and economic potential of both TBS and Dundas, we have
adopted a risked closeology valuation approach, by computing an NPV for Dundas of
$223m and then applying a three-tiered risked probability calculation to arrive at a value
of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS
and Bluejay its Feasibility Study results, this number is likely to be revised upwards very
rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder
value.

We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which
4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth
of valuation catalysts anticipated across the project portfolio in the coming months, we
recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential
15 times plus uplift from the current share price.

[waterloo01] 14/12/2017 20:04

It's a pretty full note on both programs. Talk of $1bn market opportunity for Rdz

[luminoso] 14/12/2017 19:44

Is there any rationale in the note, waterloo or just a target ?

[waterloo01] 14/12/2017 12:20

Panmure have put a note out with a target price of £3.42.

[hugus maximus] 14/12/2017 08:34

Dreary share price on account of Tax-loss Selling in the USA? (Though small rally at NASDAQ final last night)

[luminoso] 11/12/2017 12:00

" have been campaigning since June 2106 to REMAIN IN."

Bloody hell, I knew the negotiations were interminable, but never realised they were that long drawn out !

[waterloo01] 08/12/2017 17:45

Great news abut a soft Brexit and regulatory alignment. Best of bad idea IMO.